Publications (65) Marisol Aymerich Soler publications

filter_list

2025

  1. Activation of central cannabinoid type 2 receptors, but not on peripheral immune cells, is required for endocannabinoid-mediated neuroprotection in Parkinson's disease

    Brain, Behavior, and Immunity, Vol. 128, pp. 600-611

  2. Chronic traumatic brain injury induces neurodegeneration, neuroinflammation, and cognitive deficits in a T cell-dependent manner

    Brain Research, Vol. 1850

  3. Complementary roles of glial cells in generating region-specific neuroinflammatory responses and phagocytosis in Parkinson’s disease

    Neural Regeneration Research, Vol. 20, Núm. 10, pp. 2917-2918

  4. Short-chain fatty acids are a key mediator of gut microbial regulation of T cell trafficking and differentiation after traumatic brain injury

    Experimental Neurology, Vol. 392

2024

  1. Nigrostriatal degeneration determines dynamics of glial inflammatory and phagocytic activity

    Journal of Neuroinflammation, Vol. 21, Núm. 1

2023

  1. El núcleo: parte II, transcripción y maduración del ARN, y estructura del nucléolo

    Biología celular biomédica (Elsevier), pp. 175-197

  2. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease

    GLIA, Vol. 71, Núm. 3, pp. 571-587

  3. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models

    Neurobiology of Disease, Vol. 183

2021

  1. Expression of endothelial nox5 alters the integrity of the blood-brain barrier and causes loss of memory in aging mice

    Antioxidants, Vol. 10, Núm. 8

  2. Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

  3. Understanding the potential role of sirtuin 2 on aging: Consequences of sirt2.3 overexpression in senescence

    International Journal of Molecular Sciences, Vol. 22, Núm. 6, pp. 1-23

2020

  1. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s disease

    Diagnosis and Management in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 1 (Elsevier), pp. 557-573

  2. Cb2 receptors and neuron–glia interactions modulate neurotoxicity generated by magl inhibition

    Biomolecules, Vol. 10, Núm. 8, pp. 1-15

2019

  1. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model

    Frontiers in Immunology, Vol. 10, Núm. MAY

  2. Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions

    Journal of Neuroinflammation, Vol. 16, Núm. 1

2018

  1. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

    Biochemical Pharmacology, Vol. 157, pp. 67-84

  2. Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples

    Neurotherapeutics, Vol. 15, Núm. 3, pp. 742-750

  3. Stereological estimates of glutamatergic, GABAergic, and cholinergic neurons in the pedunculopontine and laterodorsal tegmental nuclei in the rat

    Frontiers in Neuroanatomy, Vol. 12

  4. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

    Neurobiology of Disease, Vol. 118, pp. 64-75

2017

  1. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332